-
Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Not Recruiting
More
The primary objective of phase 1 is to evaluate the safety of KTE-C19 and atezolizumab
combination regimens.
The primary objective of phase 2 is to evaluate the efficacy of KTE-C19 and atezolizumab, as
measured by complete response rate in participants with refractory diffuse large B-cell
lymphoma (DLBCL).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Ibrutinib in Combination With Corticosteroids vs Placebo in Combination With Corticosteroids in Participants With New Onset Chronic Graft Versus Host Disease (cGVHD)
Not Recruiting
More
To evaluate the safety and efficacy of ibrutinib in combination with prednisone in subjects
with newly diagnosed moderate to severe cGVHD.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies
Not Recruiting
More
The primary objective of this protocol is to provide expanded access to tabelecleucel to
participants with Epstein-Barr virus-associated diseases and malignancies for whom there are
no other appropriate therapeutic options, and who are not eligible to enroll in clinical
studies designed to support the development and registration of tabelecleucel.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Efficacy of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Subjects With Relapsed/Refractory Diffuse Large B Cell Lymphoma
Not Recruiting
More
The purpose of this study is to evaluate whether axicabtagene ciloleucel therapy improves the
clinical outcome compared with standard of care second-line therapy in patients with
relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)
Not Recruiting
More
The purpose of this study is to compare relapse-free survival between participants with
FLT3/ITD AML in first morphologic complete remission (CR1) who undergo hematopoietic stem
cell transplant (HCT) and are randomized to receive gilteritinib or placebo beginning after
the time of engraftment for a two year period.
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
A Study of Ruxolitinib in Combination With Corticosteroids for the Treatment of Steroid-Refractory Acute Graft-Versus-Host Disease (REACH-1)
Not Recruiting
More
The purpose of this study is to assess the efficacy of ruxolitinib in combination with
corticosteroids in subjects with Grades II to IV steroid-refractory acute graft-versus-host
disease (GVHD).
Stanford is currently not accepting patients for this trial.
For more information, please contact Cancer Clinical Trials Office (CCTO), 650-498-7061.
Stanford Investigators
View full details
-
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors
Recruiting
More
This randomized phase III trial studies how well standard-dose combination chemotherapy works
compared to high-dose combination chemotherapy and stem cell transplant in treating patients
with germ cell tumors that have returned after a period of improvement or did not respond to
treatment. Drugs used in chemotherapy, such as paclitaxel, ifosfamide, cisplatin,
carboplatin, and etoposide, work in different ways to stop the growth of tumor cells, either
by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Giving chemotherapy before a stem cell transplant stops the growth of cancer cells by
stopping them from dividing or killing them. Giving colony-stimulating factors, such as
filgrastim or pegfilgrastim, and certain chemotherapy drugs, helps stem cells move from the
bone marrow to the blood so they can be collected and stored. Chemotherapy is then given to
prepare the bone marrow for the stem cell transplant. The stem cells are then returned to the
patient to replace the blood-forming cells that were destroyed by the chemotherapy. It is not
yet known whether high-dose combination chemotherapy and stem cell transplant are more
effective than standard-dose combination chemotherapy in treating patients with refractory or
relapsed germ cell tumors.
Stanford Investigators
View full details
-
Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant
Recruiting
More
This phase II trial studies how well ibrutinib works in treating patients after a donor stem
cell transplant for lymphoma that is not responding to treatment or has come back. Ibrutinib
may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Stanford Investigators
View full details
-
Donor Regulatory T Cells in Treating Patients With Visceral Acute Graft-versus-Host Disease After Stem Cell Transplant
Not Recruiting
More
This phase I trial studies the side effects and best dose of donor regulatory T cells in
treating patients with graft-versus-host disease affecting the liver or gastrointestinal
organs (visceral) within 100 days (acute) after undergoing a stem cell transplant.
Graft-versus-host disease occurs when donor immune cells infused in a stem cell transplant
attack the gut, skin, liver, or other organ systems of the patient. Regulatory T cells are a
type of immune cell that may be able to reduce the attack of the donor's immune cells on the
patient's normal cells and help treat graft-vs-host disease.
Stanford is currently not accepting patients for this trial.
For more information, please contact Joanne Otani, 650-721-2372.
Stanford Investigators
View full details
-
A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)
Recruiting
More
This is a single-arm, open-label, multicenter, Phase 1 study evaluating the safety and
efficacy of CTX130 in subjects with relapsed or refractory T or B cell malignancies.
Stanford Investigators
View full details
-
CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma
Recruiting
More
This phase 2 trial studies how well cluster of differentiation 8 (CD8)+ memory T-cells work
as a consolidative therapy following a donor non-myeloablative hematopoietic cell transplant
in treating patients with leukemia or lymphoma. Giving total lymphoid irradiation and
anti-thymocyte globulin before a donor hematopoietic cell transplant helps stop the growth of
cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells.
When the healthy stem cells from a donor are infused into the patient they may help the
patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
Sometimes the transplanted cells from a donor can make an immune response against the body's
normal cells (called graft-versus-host disease). Giving cyclosporine and mycophenolate
mofetil after the transplant may stop this from happening. Once the donated stem cells begin
working, the patient's immune system may see the remaining cancer cells as not belonging in
the patient's body and destroy them. Giving an infusion of the donor's white blood cells,
such as CD8+ memory T-cells, may boost this effect and may be an effective treatment to kill
any cancer cells that may be left in the body (consolidative therapy).
Stanford Investigators
View full details
-
Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma
Not Recruiting
More
Non-myeloablative approach for allogeneic transplant is a reasonable option, especially given
that the median age at diagnosis is 55-60 years and frequently present compromised skin in
these patients, which increases the risk of infection. Therefore, we propose a clinical study
with allogeneic HSCT using a unique non-myeloablative preparative regimen, TLI/ATG, to treat
advanced MF/SS.
Stanford is currently not accepting patients for this trial.
For more information, please contact Michelle Chin, 650-721-4183.
Lead Sponsor
Stanford Investigators
View full details
-
Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies
Recruiting
More
The primary objectives of this study are:
Cohort 1: to provide access to brexucabtagene autoleucel (KTE-X19) for individuals with
relapsed or refractory (r/r) mantle cell lymphoma (MCL) until KTE-X19 is commercially
available
Cohort 2: To provide access to KTE-X19 for individuals with r/r MCL whose commercially
manufactured product did not meet commercial release specification(s)
Stanford Investigators
View full details
-
TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPD
Not Recruiting
More
To evaluate the feasibility and safety of TLI/ATG conditioning for allogeneic HCT for elderly
patients with advanced stage MDS and MPD.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Lead Sponsor
Stanford Investigators
View full details
-
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
Not Recruiting
More
Acute myeloid leukemia (AML) is a cancer of the bone marrow that mostly affects older adults.
Even with the best chemotherapy, two-year disease-free survival is achieved in a minority of
patients. Bone marrow transplantation from a sibling donor may improve cure rates; however,
patients over 50 years of age have a high risk of complications and therefore generally are
excluded from this treatment option. Recently our group developed a transplantation strategy
for older cancer patients that protects against transplant-associated complications, yet does
not interfere with the ability of the transplanted donor cells to destroy cancer cells. With
this new method, we can now safely evaluate transplantation as a curative therapy for AML
patients over the age of 50. We have assembled clinical and scientific researchers throughout
the state of California to study and compare bone marrow transplantation using our new
approach with the best standard of care chemotherapy in AML patients over the age of 50. The
results of this study have the potential to establish a new treatment standard that will
improve survival of older AML patients.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 650-725-1647.
Lead Sponsor
Stanford Investigators
View full details
-
Protocol For A Research Database For Hematopoietic Stem Cell Transplantation, Other Cellular Therapies and Marrow Toxic Injuries
Recruiting
More
The primary purpose of the Research Database is to have a comprehensive source of
observational data that can be used to study HSC transplantation and cellular therapies.
A secondary purpose of the Research Database is to have a comprehensive source of data to
study marrow toxic injuries.
Objectives:
To learn more about what makes stem cell transplants and cellular therapies work well such
as:
- Determine how well recipients recover from their transplants or cellular therapy;
- Determine how recovery after a transplant or cellular therapy can be improved;
- Determine how a donor's or recipient's genetics impact recipient recovery after a
transplant or cellular therapy;
- Determine how access to transplant or cellular therapy for different groups of patients
can be improved;
- Determine how well donors recover from the collection procedures.
Stanford Investigators
View full details
-
A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease
Not Recruiting
More
To determine if subjects with steroid refractory cGVHD can tolerate imatinib mesylate and
whether their cGVHD responds to imatinib mesylate.
Stanford is currently not accepting patients for this trial.
For more information, please contact Joanne Otani, 6507212372.
Stanford Investigators
View full details
-
Phase 1 Infused Donor T Regulatory Cells in Steroid Dependent/Refractory Chronic GVHD
Not Recruiting
More
Chronic graft versus host disease (cGVHD) is a common complication of bone marrow or
hematopoietic cell transplant from another person (allogeneic transplant). This study will
determine if subjects with steroid dependent/refractory cGVHD can tolerate infusion of donor
regulatory T cells and whether their cGVHD responds to the infusion.
Stanford is currently not accepting patients for this trial.
For more information, please contact Joanne Otani, 650-721-2372.
Stanford Investigators
View full details
-
Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders
Not Recruiting
More
Allogeneic stem cell transplantation (transplant of blood cells from another individual) is a
treatment option for patients with myelodysplasia or myeloproliferative Disorders. During the
course of this study, it will be evaluated whether a particular type of blood cell, called a
cytokine-induced killer (CIK) cell, may add benefit to allogeneic stem cell transplantation.
CIK cells are present in small quantities in the bloodstream but their numbers can be
expanded after a brief period of nurturing in a laboratory.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Peripheral Blood Stem Cell Transplant vs Bone Marrow Transplant in Individuals With Hematologic Cancers (BMT CTN 0201)
Not Recruiting
More
The study is designed as a Phase III, randomized, open label, multicenter, prospective,
comparative trial of granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood
stem cells (PBSC) versus marrow from unrelated donors for transplantation in patients with
hematologic malignancies. Recipients will be stratified by transplant center and disease risk
and will be randomized to either the PBSC or marrow arm in a 1:1 ratio.
Stanford is currently not accepting patients for this trial.
For more information, please contact Kate Tierney, 6507257063.
Stanford Investigators
View full details
-
High Dose Chemotherapy and Allogeneic Hematopoietic Cell Transplant for Non-Hodgkin's Lymphoma
Not Recruiting
More
To evaluate the role of allogeneic hematopoietic cell transplantation in the treatment of
NHL.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL
Not Recruiting
More
Mantle cell lymphoma (MCL) is a sub-type of non-Hodgkin's lymphoma (NHL) which is generally
considered incurable with current therapy. Participants will receive an autologous vaccine
against their individual lymphoma after undergoing stem cell transplantation. This
vaccination may prolong the time which patients will stay in remission from their disease.
Stanford is currently not accepting patients for this trial.
For more information, please contact Ami Okada, 6507254968.
Stanford Investigators
View full details
-
Safety and Efficacy Study of an Anti-CD20 Monoclonal Antibody (AME-133v) to Treat Non-Hodgkin's Lymphoma
Not Recruiting
More
This study is designed to provide evidence of the safety and a preliminary understanding of
the efficacy of AME 133v.
Stanford is currently not accepting patients for this trial.
For more information, please contact Maria Ahern, 6504935000.
Stanford Investigators
View full details
-
Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma
Not Recruiting
More
RATIONALE: Vaccines made from a person's cancer cells may make the body build an effective
immune response to kill cancer cells. Colony-stimulating factors, such as GM-CSF, may
increase the number of immune cells found in bone marrow or peripheral blood and may
stimulate the immune system in different ways and stop cancer cells from growing.
PURPOSE: This phase II trial is studying how well giving vaccine therapy together with GM-CSF
works in treating patients with progressive B-cell non-Hodgkin's lymphoma.
Stanford is currently not accepting patients for this trial.
For more information, please contact Mayita Romero, 6507256452.
Stanford Investigators
View full details
-
Bone Marrow Grafting for Leukemia and Lymphoma
Recruiting
More
The purpose of this study is to obtain tissue samples for ongoing studies regarding
transplant outcomes and complications.
Lead Sponsor
Stanford Investigators
View full details
-
Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level
Not Recruiting
More
The purpose of this study is to learn the effects of brentuximab vedotin (SGN-35), an
investigational medication, on patients with cutaneous T cell lymphoma (CTCL), specifically
mycosis fungoides (MF) and Sezary syndrome (SS). Despite a wide range of therapeutic options,
the treatments are associated with short response duration, thus this condition is largely
incurable. This investigational drug may offer less toxicity than standard treatments and
have better tumor specific targeting.
Stanford is currently not accepting patients for this trial.
For more information, please contact Kokil Bakshi, 650-421-6370.
Stanford Investigators
View full details
-
Double Cord Versus Haploidentical (BMT CTN 1101)
Not Recruiting
More
Hematopoietic cell transplants (HCT)are one treatment option for people with leukemia or
lymphoma. Family members,unrelated donors or banked umbilical cordblood units with similar
tissue type can be used for HCT. This study will compare the effectiveness of two new types
of bone marrow transplants in people with leukemia or lymphoma: one that uses bone marrow
donated from family members with only partially matched bone marrow; and, one that uses two
partially matched cord blood units.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation
Recruiting
More
This research study is studying a drug called obinutuzumab as a means of preventing chronic
Graft vs. Host Disease (cGVHD).
Stanford Investigators
View full details
-
Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell
Not Recruiting
More
For patients with hematologic malignancies undergoing allogeneic myeloablative (MA) HCT with
a T cell depleted graft, the infusion of naturally occurring regulatory T cells with
conventional T cells (T cell add back) in pre-defined doses and ratios will reduce the
incidence of acute graft vs host disease while augmenting the graft vs leukemia effect and
improving immune reconstitution.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma
Not Recruiting
More
Mixed chimerism transplantation is an approach to allogeneic transplants that attempts to
decrease regimen-related toxicity by using non-myeloablative preparatory regimens; establish
mixed chimerism using low dose total body irradiation along with immunosuppression using
cyclosporine and mycophenolate mofetil; suppress graft-vs-host and host-vs-graft reactions to
allow a mixed chimeric state to be established, encourage tolerance and prevent graft-vs-host
disease (GvHD) during the mixed chimerism period and use donor lymphocyte infusions to
convert the patient to a full chimera while developing a graft-vs-tumor effect.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Stanford Investigators
View full details
-
Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder
Not Recruiting
More
RATIONALE: Cyclosporine eye drops may prevent graft-versus-host disease of the eye in
patients who have undergone donor stem cell transplant for hematologic cancer or bone marrow
failure disorder.
PURPOSE: This randomized phase I trial is studying how well cyclosporine eye drops work in
preventing graft-versus-host disease of the eye in patients who have undergone donor stem
cell transplant for hematologic cancer or bone marrow failure disorder.
Stanford is currently not accepting patients for this trial.
For more information, please contact Joanne Otani, 6507212372.
Stanford Investigators
View full details
-
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
Not Recruiting
More
The purpose of this trial is to develop an alternative treatment for patients with poor risk
non-Hodgkin's lymphoma. This trial uses a combination of high dose chemotherapy with stem
cell transplant using the patient's own cells. This is followed with non-myeloablative
transplant using stem cells from a related or unrelated donor to try and generate an
anti-lymphoma response from the new immune system.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Lead Sponsor
Stanford Investigators
View full details
-
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
Not Recruiting
More
Acute Graft-versus-Host-Disease (GVHD) is an important cause of morbidity and mortality after
allogeneic hematopoietic stem cell transplantation (HSCT). This study aims to determine if
any of three new GVHD prophylaxis approaches improves the rate of GVHD and relapse free
survival at one year after transplant compared to the current standard prophylaxis regimen.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT
Not Recruiting
More
A continuation study of sirolimus and mycophenolate mofetil (MMF) for graft-vs-host disease
(GvHD) prophylaxis for patients undergoing matched related allogeneic hematopoietic stem cell
transplantation (HSCT) for acute and chronic leukemia, myelodysplastic syndrome (MDS), high
risk non-Hodgkin lymphoma (NHL), or Hodgkin lymphoma (HL)
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Acute Graft-versus-Host Disease Treatment (BMT CTN 0802)
Not Recruiting
More
The study is a Phase III, randomized double blind, placebo controlled, and trial evaluating
the addition of Mycophenolate mofetil (MMF) vs. placebo to systemic corticosteroids as
initial therapy for acute Graft Vs Host Disease (GVHD). The primary endpoint will be GVHD
free survival at Day 56 post randomization.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Stanford Investigators
View full details
-
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation
Not Recruiting
More
This phase II trial studies donor atorvastatin treatment for the prevention of severe acute
graft-versus-host disease (GVHD) in patients undergoing myeloablative peripheral blood stem
cell (PBSC) transplantation. Giving chemotherapy and total-body irradiation (TBI) before a
donor PBSC transplant helps stop the growth of cancer cells. It may also prevent the
patient's immune system reject the donor's stem cells. When the healthy stem cells from a
donor are infused into the patient they may help the patient's bone marrow make stem cells,
red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a
donor can make an immune response against the body's normal cells. Giving atorvastatin to the
donor before transplant may prevent this from happening.
Stanford is currently not accepting patients for this trial.
For more information, please contact Leah Galvez, 650-725-7951.
Stanford Investigators
View full details
-
Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)
Not Recruiting
More
This study is designed to compare long-term outcomes among patients randomized on the BMT CTN
0702 protocol (NCT01109004), "A Trial of Single Autologous Transplant with or without
Consolidation Therapy versus Tandem Autologous Transplant with Lenalidomide Maintenance for
Patients with Multiple Myeloma". It is hypothesized that use of novel anti-myeloma agents
will improve long-term progression-free survival (PFS) after high-dose melphalan followed by
autologous hematopoietic cell transplantation (HCT) as compared to a second autologous
transplantation.
Stanford is currently not accepting patients for this trial.
For more information, please contact Kashif Naseem, 650-724-3155.
Stanford Investigators
View full details
-
Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801)
Not Recruiting
More
This study is designed as a combined Phase II/III, randomized, open label, multicenter,
prospective comparative study of sirolimus plus prednisone versus
sirolimus/calcineurin-inhibitor plus prednisone for the treatment of chronic GVHD. Patients
will be stratified by transplant center and will be randomized to an experimental arm of one
of the two pre-specified experimental arms (sirolimus + prednisone or the comparator arm of
sirolimus + calcineurin inhibitor + prednisone) in a 1:1 ratio.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML
Not Recruiting
More
This phase I/II trial is studying the side effects and best way to give nilotinib when given
alone or sequentially after imatinib mesylate after donor stem cell transplant in treating
patients with acute lymphoblastic leukemia or chronic myelogenous leukemia. Nilotinib and
imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed
for cell growth.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 6507230822.
Stanford Investigators
View full details
-
Allo vs Hypomethylating/Best Supportive Care in MDS (BMT CTN 1102)
Not Recruiting
More
This study is designed as a multicenter trial, with biological assignment to one of two study
arms; Arm 1: Reduced intensity conditioning allogeneic hematopoietic cell transplantation
(RIC-alloHCT), Arm 2: Non-Transplant Therapy/Best Supportive Care.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Allogeneic Transplantation Using Total Lymphoid Irradiation (TLI) and Anti-Thymocyte Globulin (ATG) for Older Patients With Hematologic Malignancies
Not Recruiting
More
To measure how frequently and to what degree a complication of transplant cell acute graft
versus host disease (GvHD) occurs.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Lead Sponsor
Stanford Investigators
View full details
-
Targeted Therapy of Bronchiolitis Obliterans Syndrome
Not Recruiting
More
This phase II trial studies how well giving fluticasone propionate, azithromycin, and
montelukast sodium (FAM) together works in treating patients with bronchiolitis obliterans
who previously underwent stem cell transplant. FAM may be an effective treatment for
bronchiolitis obliterans
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 650-723-0822.
Stanford Investigators
View full details
-
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)
Not Recruiting
More
The study is designed as a Phase III, multicenter trial of tandem autologous transplants plus
maintenance therapy versus the strategy of single autologous transplant plus consolidation
therapy with lenalidomide, bortezomib and dexamethasone (RVD) followed by maintenance therapy
or single autologous transplant plus maintenance therapy as part of upfront treatment of
multiple myeloma (MM). Lenalidomide will be used as maintenance therapy for three years in
all arms.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 6507230822.
Stanford Investigators
View full details
-
Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)
Not Recruiting
More
The clinical trial is a Phase 1/2a, open-label, multi-center, dose-escalation study to
evaluate the safety, tolerability and pharmacokinetic profile of RGI-2001 in patients
undergoing AHSCT, with radiation or non-radiation myeloablative preparative treatment.
The study will be separated into two parts; a dose escalation phase to assess safety,
followed by a large expansion phase to further evaluate the pharmacologic effects of either a
Maximum Tolerated Dose, Maximum Feasible Dose or optimal pharmacologically active dose of
RGI-2001. The initial dose escalation safety portion of the study (Part 1) will include
higher risk patients and limit the unrelated donor transplants. After safety is established
in part 1 of the study, the second portion of the study will expand the enrollment criteria
and allow transplantation by either related or unrelated donors.
This study will endeavor to identify the dose range at which RGI-2001 has an acceptable
safety profile, at which biologic activity is observed, and to guide possible dose levels to
utilize in later phase studies based on biological activity.
Stanford is currently not accepting patients for this trial.
For more information, please contact Physician Referrals, 6507230822.
Stanford Investigators
View full details
-
Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment
Not Recruiting
More
To characterize the molecular and cell biology of the tumor cells in lymphoma. The mechanism
of monoclonal antibody treatment by rituximab or epratuzumab will also be examined.
Stanford is currently not accepting patients for this trial.
For more information, please contact Mayita Romero, 6507256452.
Lead Sponsor
Stanford Investigators
View full details
-
Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT
Not Recruiting
More
The purpose of this study is to determine if double autologous then allogeneic hematopoietic
cell transplant may offer an improved treatment option for patients with relapsed diffuse
large B-cell lymphoma (DLBCL) who are not likely to be cured by the conventional
transplantation regimen.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
Transplantation for Patients With Chronic Lymphocytic Leukemia
Not Recruiting
More
To evaluate the role of high dose therapy and autologous or allogeneic hematopoietic cell
transplantation for the treatment of chronic lymphocytic leukemia.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
-
A Phase 3 Study of Brentuximab Vedotin (SGN-35) in Patients at High Risk of Residual Hodgkin Lymphoma Following Stem Cell Transplant (The AETHERA Trial)
Not Recruiting
More
This is a randomized, double-blind, placebo-controlled, multicenter phase 3 trial to evaluate
the efficacy and safety of brentuximab vedotin (SGN-35) and best supportive care (BSC)
compared to placebo and BSC in treatment of residual Hodgkin lymphoma (HL) following
autologous stem cell transplant (ASCT).
Stanford is currently not accepting patients for this trial.
For more information, please contact Sarah Robeson, 6507251647.
Stanford Investigators
View full details
-
Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG
Not Recruiting
More
To evaluate the toxicity and tolerability of this tandem autologous/allogeneic transplant
approach for patients with advanced stage multiple myeloma.
Stanford is currently not accepting patients for this trial.
For more information, please contact BMT Referrals, 6507230822.
Lead Sponsor
Stanford Investigators
View full details
